COVID-19 Pandemic
Applications received by Swissmedic for the authorisation (or authorisation extension in the case of vaccines) for COVID-19 vaccines and therapeutic agents against COVID-19 and the current status of the authorisation procedures.
On this page you’ll find answers to frequently asked questions about mRNA vaccines.
All about the vaccines - briefly and concisely explained
Vaccines: Rapid solution for new diseases?
Swismedic - The way a vaccination works
How an mRNA vaccine works
How a vector vaccine works?
How a protein vaccine works
How is the safety of vaccines monitored?
Communication regarding COVID-19
01.02.2023
Licences in accordance with art. 22 para. 3 of the COVID 19 Ordinance 3
23.01.2023
Update of the validity period of EMA GMP certificates
25.11.2022
16,212 reports of suspected adverse vaccination reactions evaluated
18.11.2022
Application submitted for Spikevax Bivalent Original / Omicron BA.4-5 (mRNA-1273.222)
04.11.2022
Results from laboratory analyses now available
02.11.2022
risks currently being investigated
10.10.2022
Comirnaty Bivalent Original / Omicron BA.1 (tozinameran / riltozinameran) from Pfizer authorised from age 18
22.09.2022
Application submitted for Comirnaty Original/Omicron BA.4-5
